The trial was tiny, just 16 patients, but it’s eliciting a sentiment not normally associated with this brutal disease of pancreatic cancer: hope,” Jarvis writes.

The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the blood of someone who doesn’t have the disease. When used alongside the existing CA 19-9 test, it was able to diagnose early-stage pancreatic cancer with 85% accuracy.

These vaccines work by stimulating the body's immune response against cancer cells, often by training immune cells (like T cells) to target specific tumor proteins.

Pancreatic cancer is one of the deadliest and most difficult-to-detect forms of cancer. It kills nearly half a million people annually and has a five-year survival rate of less than 15 percent. The main challenge is that there are no reliable tools to detect the disease at early stages,

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized.

A new study published in the journal Nature emphasizes the promise of a personalized vaccine, autogene cevumeran, in treating pancreatic cancer. The research shows that this novel therapeutic vaccine for cancer can stimulate the immune system and possibly reduce the risk of disease recurrence after surgery.

The five-year survival rate of people diagnosed with pancreatic cancer is currently 13 percent. Two breakthroughs are bringing hope for successfully treating this malignancy.

Paired with an existing test, this could become a life-saving diagnostic tool for people with a notoriously deadly form of cancer.

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by measuring cancer-associated protease activity in a small amount of blood.

Pancreatic cancer remains difficult to treat, and is responsible for around 8 percent of all cancer deaths.It also has one of the lower longterm survival rates with only about 13 percent of patients surviving more than five years.

Pancreatic cancer is the third leading cause of cancer-related deaths in the country. The Ramone Foundation is hosting a charity boxing event to ease that burden and fund research.

A study published last month in Nature underscores the potential for a new personalized pancreatic cancer vaccine to keep the disease from coming back. The trial was tiny, just 16 patients ...